Table 2.
Incidence of the highest grade of acute adverse effects (CTC-Classification [NIH]) observed during treatment according to age
| Effect | Highest grade of adverse effect non-elderly (n = 77) | Highest grade of adverse effect elderly (n = 25) | ||
|---|---|---|---|---|
| 1/2 n (%) |
3/4 n (%) |
1/2 n (%) |
3/4 n (%) |
|
| Leukopenia | 43 (56) | 21 (27) | 10 (40) | 8 (32) |
| Anemia | 29 (38) | 2 (3) | 7 (28) | 1 (4) |
| Diarrhea | 26 (34) | 1 (1) | 8 (32) | 1 (4) |
| Nausea | 24 (31) | 1 (1) | 10 (40) | 1 (4) |
| Thrombopenia | 20 (26) | 0 | 12 (48) | 0 |
| Skin hyperpigmentation | 11 (14) | 0 | 2 (8) | 0 |
| Epitheliolysis | 10 (13) | 0 | 2 (8) | 0 |
| Erythema | 8 (10) | 0 | 5 (20) | 0 |
| Creatinine clearance below lower normal limit | 7 (9) | 0 | 1 (4) | 0 |
| Emesis | 7 (9) | 0 | 4 (16) | 0 |
| Constipation | 5 (6) | 0 | 1 (4) | 0 |
| ALT increasea | 5 (6) | 0 | 0 | 0 |
| AST increaseb | 3 (4) | 0 | 0 | 0 |
| Hypocalcemia | 3 (4) | 0 | 1 (4) | 0 |
| Loss of appetite | 3 (4) | 0 | 1 (4) | 0 |
| Creatinine increase | 2 (3) | 0 | 0 | 0 |
| Cystitis | 2 (3) | 0 | 0 | 0 |
| Hypokalemia | 2 (3) | 0 | 0 | 0 |
| Pruritus | 2 (3) | 0 | 0 | 0 |
| Seizure | 1 (1) | 1 (1) | 0 | 0 |
| Enteritis | 1 (1) | 0 | 0 | 0 |
| Fever | 1 (1) | 0 | 0 | 0 |
| Dizziness | 0 | 0 | 1 (4) | 0 |
| Smell alteration | 0 | 0 | 1 (4) | 0 |
| Taste alteration | 0 | 0 | 1 (4) | 0 |
aALT alaninaminotransferase, above upper normal limit
bAST aspartataminotransferase, above upper normal limit